Biochemical Abnormalities in OPC Poisoning and Its Prognostic Significance by Alen, Binny
BIOCHEMICAL ABNORMALITIES IN OPC 
POISONING AND ITS PROGNOSTIC SIGNIFICANCE 
Dissertation submitted to 
The Tamilnadu Dr.M.G.R. Medical University 
In partial fulfilment of the regulations 
for the award of the degree of 
M.D. General Medicine – [Branch - 1] 
DEPARTMENT OF GENERAL MEDICINE 
K.A.P.VISWANATHAM GOVERNMENT MEDICAL COLLEGE 
& 
M.G.M. GOVERNMENT HOSPITAL, 
TIRUCHIRAPALLI. 
 
THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
APRIL-2017 
 BONAFIDE CERTIFICATE 
 
 This is to certify that the dissertation entitled “BIOCHEMICAL 
ABNORMALITITES IN OPC POISONING AND ITS PROGNOSTIC 
SIGNIFICANCE” is a bonafide original work of Dr. Alen Binny in partial 
fulfilment of the requirements of M.D General Medicine [Branch-1] 
examination of The Tamilnadu Dr.M.G.R Medical University to be held in 
April 2017. 
 
 
 
 
 
 
 
 
Prof.Dr.N.K.Senthilnathan M.D., 
Professor and HOD, 
Department of General Medicine, 
K.A.P.V Govt. Medical College, 
M.G.M.G.H, Trichy 
Prof.Dr.S.Mary Lilly M.D., 
DEAN, 
K.A.P.V Govt. Medical 
College, 
M.G.M.G.H, Trichy. 
  
DECLARATION 
 
I solemnly declare that the dissertation titled “BIOCHEMICAL 
ABNORMALITITES IN OPC POISONING AND ITS PROGNOSTIC 
SIGNIFICANCE” is done by me at K.A.P.VISWANATHAM GOVT 
MEDICAL COLLEGE, TIRUCHIRAPALLI-1 under the guidance and 
supervision of Prof.Dr.N.K.Senthilnathan, M.D. This dissertation is submitted 
to The Tamil Nadu Dr. M.G.R. Medical University towards the partial 
fulfilment of the requirements for the award of M.D Degree [Branch-1] in 
General Medicine. 
 
 
 
Place: 
Date: 
Dr. Alen Binny, 
Postgraduate student, 
M.D. General medicine 
K.A.P.V Government Medical college, 
  M.G.M.G.H, 
Tiruchirappalli. 
  
ACKNOWLEDGEMENT 
I express my sincere gratitude to the Prof. Dr. S. MARY LILLY M.D., 
DEAN, K.A.P.V. Government Medical College, Tiruchirappalli for allowing 
me to undertake this study in this prestigious institution.  
I am extremely grateful to Prof. Dr. N. K. SENTHILNATHAN, M.D., 
Professor and Head of the Department of General medicine, K.A.P.V. Govt 
Medical College and Hospital for permitting me to carry out this study and for 
his constant encouragement and guidance.  
I take immense pleasure in expressing my sincere thanks to               
Prof. Dr. K. NIRMALADEVI M.D. (Biochemistry), DCH., Department of 
Biochemistry, K.A.P.V. Govt. Medical College, Trichy for permitting me to do 
all biochemical analysis in our Central Laboratory and for her constant 
encouragement and guidance. 
I thank my unit Assistant Professors Dr. Barathiraja M.D., Dr. Kannan 
M.D, D.M (Neuro), Dr. Youmesh M.D., for their continuous motivation and 
valuable guidance throughout my work.  
I sincerely thank all the Assistant Professors of the Department of 
General Medicine for their co-operation and guidance.  
I whole heartedly thank my parents, colleagues, friends and staff of our 
hospital for their support for this work.  
I owe my sincere thanks to all the patients for their kind co-operation 
throughout the study.  
 
 
CONTENT 
 
S. NO TITLE PAGE NO 
1 INTRODUCTION 1 
2 AIMS AND OBJECTIVES 4 
3 MATERIALS AND METHODS 5 
4 REVIEW OF LITERATURE 10 
5 STATISTICS 38 
6 DISCUSSION 70 
7 CONCLUSION 76 
8 LIMITATIONS 77 
9 BIBLIOGRAPHY 78 
10 ANNEXURES 
a. Data collection Proforma 
b. Consent and Patient Information letter 
c. Ethical committee clearance certificate 
d. Plagiarism Report 
e. Master Chart 
f. Abbreviations 
 
87 
 
1 
 
INTRODUCTION 
 
The modern world thrives well on revolution in the agricultural practices 
that has resulted in a massive thrust in agricultural productivity. One of the 
most important step in green revolution is pesticides. Pesticides are a class of 
toxic substances that are intentionally released into the environment for the 
greater good it does that exceeds their toxicological concerns. In the developing 
world, Poisoning is a common method of suicide (1). Pesticide poisoning is a 
major health hazard in the developing world(2).  Millions of people are exposed 
to these dangerous chemicals because of the occupational hazards and also 
because of unsafe storage practices(3). However it is the deliberate self-
poisoning that causes majority of the deaths and a difficult health strategy to 
manage among health services, especially in Asia. According to World health 
organisation report, about three million cases of pesticide poisoning occur 
every year worldwide and most of them are in Asia, among which 50% of them 
are organophosphate poisoning. The exact rate of OP poisoning in India is not 
clear because of under reporting and lack of data. India is an agricultural 
country and OP compounds are used greatly for the agriculture in India. 
Therefore the access to these harmful pesticide substances is so easy. In many 
reports from India, rate of suicidal poisoning with Opc ranges from 10 to 
43%(4). Among these patients mortality rate is as high as 20 to 70%(5). In 
developed countries like United Kingdom, the death due to OP compounds 
relate to only 1%. This is because in developing countries like India the 
facilities for early diagnosis and treatment are very limited. The morbidity and 
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mortality in these patients depends on the time lag between the exposure and 
the onset of management. So it is very important to recognise the whole 
spectrum of symptoms in OP poisoning. Organophosphorus compounds inhibit 
acetyl cholinesterase and butyryl cholinesterase enzymes resulting in  excess 
acetyl choline in the neuromuscular junction  causing overstimulation at the 
cholinergic synapses(6). The symptoms are classified into muscarinic, nicotinic 
and central depending on the site of the compound over the respective 
receptors. Urination, lacrimation, emesis, miosis, excessive salivation, 
bradycardia, diarrhoea, and wheezing are the muscarinic features. Nicotinic 
features are paresis, fasciculation, tachycardia, and hypertension. Central 
features includes confusion, anxiety, seizures, ataxia and psychosis(7). The need 
for newer biomarkers in relation to OP poisoning started a very long time ago. 
OP labelled albumin in plasma, blood beta-glucuronidase and paraxonase status 
were suggested by some scientists to be very reliable marker for both diagnosis 
of the poisoning and prognosis. But these assays are not available widely and 
are very costly. In a limited resourced country like India, we need cheap and 
easily measurable biomarkers. Many studies were conducted regarding this and 
were shown that Serum cholinesterase can be a useful tool in the diagnosis of 
OP poisoning. But its role in prognostication is very minimal. A number of 
recent studies were conducted using parameters like liver enzymes, serum 
amylase and serum CPK as newer markers and their correlation with severity 
and prognosis of OP poisoning(8-11). Our study was conducted to assess 
parameters like CPK-MB, Serum potassium, Troponin I in correlation with 
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Serum cholinesterase along with other liver enzymes, and serum amylase to 
predict the severity and prognosis in OP poisoning patients. 
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AIMS AND OBJECTIVES  
1. TO MEASURE SERUM ACETYLCHOLINESTERASE, SERUM 
ELECTROLYTES, LIVER ENZYMES, AMYLASE, CPK, CPK-MB, 
AND TROPONIN I, IN ACUTE ORGANOPHOSPHORUS 
POISONING 
2. TO ANALYSE THE CORRELATION BETWEEN THESE 
BIOCHEMICAL PARAMETERS AND SERUM 
ACETYLCHOLINESTERASE LEVELS  
3. TO ANALYSE THE VALIDITY OF THESE BIOCHEMICAL 
PARAMETERS IN PREDICTION OF SEVERITY AND PROGNOSIS 
IN OP POISONING 
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MATERIALS AND METHODS 
SOURCE OF DATA:  
The present Study was done at Mahatma Gandhi Memorial Govt. 
Hospital attached with K.A.P.V. Govt. Medical College, Tiruchirappalli. 
STUDY DESIGN:  
Cross-sectional prospective Study  
PERIOD OF STUDY  
The study was conducted from June 2015 to June 2016.  
ETHICS COMMITTEE APPROVAL 
Approval was obtained from Institutional ethics committee.  
INCLUSION CRITERIA 
All the OP poisoning cases confirmed by history, circumstantial 
evidence of ingestion, admitted in our hospital within 12 hours of ingestion 
with characteristic clinical findings and basic laboratory investigations were 
included in the study 
EXCLUSION CRITERIA 
 Patients with feature of exposure to another compound not relating to 
OP Poison. 
 Patients with mixed poisoning; OP poisoning and any other  poison 
 Patients who has chronic alcoholism 
 Patients with history suggestive of liver disease 
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 History suggestive of myopathy 
 Patients with history of malignancy and autoimmune diseases 
 Patients with history of renal  disease 
 Patients with history of cardiac disease 
CONSENT  
An informed consent was obtained from all the participants and their 
relatives wherever necessary. 
SAMPLE COLLECTION 
When the patient was admitted in our hospital, after obtaining informed 
consent, about 5ml of blood was collected in plain tube under aseptic 
precautions. The blood was allowed to clot and serum was separated by 
centrifugation and used for the analysis of following parameters.  
ESTIMATION OF PARAMETERS 
 The enzyme creatine kinase catalyses the reaction between creatine 
phosphate and ADP to creatine and ATP. It is estimated in Kinetic mode using 
International Federation of Clinical Chemistry (IFCC) methodology. The rate 
of absorbance change at 340 nm is directly proportional to creatine kinase 
activity. It is done in a Semi-automated analyser Model BTS 350. The normal 
expected values are Males- 46-171 IU/L, Female- 24-145 IU/L at 37 degree C. 
 Creatine kinase has 3 isoforms CK-BB, CK-MM, CK-MB. CK-MM is 
present in skeletal muscle, CK-BB is present in brain and smooth muscle, while 
CK-MB is present in myocardium. CK MB is estimated using same principle 
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used to measure CK, IFCC methodology in Semi-automated analyser BTS 350. 
The normal expected value is <25 IU/L at 37 degree C. 
 Cholinesterase also known as acetyl-cholinesterase and is found mainly 
in the nerve endings and the grey matter of brain. It hydrolyses acetylcholine, 
released at the nerve endings to maintain transmission of impulses. 
Cholinesterase level in serum is a useful test of liver function and as an 
indicator of possible insecticide poisoning. During poisoning the level of 
enzymes decreases as its activity is inhibited. Cholinesterase catalyses the 
hydrolysis of butyrylthiocholine substrate forming butyrate and thiocholine. 
The decrease of absorbance is followed at 405 nm and is proportionate to the 
activity of cholinesterase in the sample. The mode of reaction is kinetic and the 
slope of reaction is decreasing. The normal reference value for male is 4620-
11500 U/L and for female is 3930-10800 U/L. 
 Alkaline phosphatase at an alkaline pH hydrolyse into p-nitrophenol 
phosphate into p-nitrophenol & inorganic phosphates. The rate of formation of 
p-nitrophenol is measured as increase in absorbance and is directly proportional 
to the ALP activity in the sample. Reference normal value for ALP is 40 – 147 
IU/L.  
AST is found in all human tissues and is present in large amounts in 
skeletal muscle tissue, renal, cardiac, and liver. Increased levels are associated 
with muscular dystrophy, liver diseases or damage, myocardial injury, etc. 
Reference normal value for AST is 5 – 34 IU/L at 37 degree C.  
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ALT is found in high concentration in liver and to a lesser extent in 
skeletal muscle, pancreas, kidney, spleen, heart, and lungs. AST levels are 
increased generally as a result of primary liver diseases such as cirrhosis, 
carcinoma, viral or toxic hepatitis and obstructive jaundice. Reference normal 
value for ALT is 0-40 IU/L at 37 degree C. All these three enzymes AST, ALT, 
ALP are estimated using IFCC method in kinetic mode.  
Alpha amylase occur in the salivary glands, fallopian tubes, and in 
pancreas. It catalyses the hydrolysis of a 2-chloro-4-nitro-phenol salt into 
chloronitrophenol. This rate of hydrolysis is measured as an increase in 
absorbance because of formation of CNP, which is directly proportional to the 
alpha amylase activity present in the sample. Amylase is estimated by CNPG3 
kinetic method. Reference normal value for Amylase is up to 90 IU/L. AST, 
ALT, Amylase and ALP are estimated in fully automated analyser EM 360. 
 Troponin I was tested using qualitative detection rapid card test. The 
cTnI one step troponin I single use kit is a rapid chromatographic immunoassay 
for the qualitative detection of cardiac Troponin I in the serum, whole blood, or 
plasma as an aid in the diagnosis of myocardial injury. Troponin I is a protein 
present in cardiac muscle and has a molecular weight of 22.5kDa. Troponin I is 
a subunit of three unit complex with Troponin T and Troponin C. When 
myocardial injury occurs Troponin I is released in blood after 4-6 hours and 
remains elevated for 6 to 10 days. The minimum detection level with this rapid 
card test is 0.5ng/ml. The relative sensitivity of this test kit is 98.5% and 
relative specificity is 98.4%. 
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During the analysis internal quality checks using Bio-Rad controls 
periodically. After the biochemical analysis, all the patients were followed till 
the end point like recovery, respiratory failure, circulatory failure, CNS 
complications and any other complications. 
Statistical Analysis 
 All the parameters were tabulated. Mean, Standard deviation were 
analysed using SPSS 20 software. All the biochemical parameters were 
correlated with serum cholinesterase using intercorrelations. Chi-square test 
was the test of significance used for qualitative variables to find the association 
between them. T test was the test of significance used for comparing 
quantitative variables with qualitative variable. One-way Anova is used as test 
of significance to assess various parameters with the compound used for 
poisoning. 
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 REVIEW OF LITERATURE  
INTRODUCTION 
Organophosphates are being used as pesticides for more than 60 years 
worldwide. These agents are used less frequently in the past 10 to 20 years 
because of the development of carbamates (12). Around the world, an estimated 
3,050,000 people are exposed to organophosphate compounds every year. The 
documented fatalities include 300,000(13) every year. Toxicity usually results 
from intentional or accidental ingestion, or exposure to agricultural pesticides 
(14). Other potential causes of organophosphate or carbamate poisoning include 
ingestion of cooking oil or contaminated fruit or, or wearing contaminated 
clothing. India being an agricultural country, Organophosphates are widely 
used to increase the production of agricultural commodities. It is estimated that 
90% of fatal insecticide poisoning occurs in developing countries(15). Using 
insecticide compounds as a mean to end life is grouped under nonviolent 
methods for suicide. Unemployment, failure in examination, social economical, 
and domestic problems are all increasing creating psychological stress to the 
victims. Such stress stimulate these people to consume these OP poisons due to 
its low price, high availability and high toxicity(16). In our country these 
compounds hence are most often are misused as suicidal agents. Since 1963 the 
incidence of OP poisoning is in a steady rise in India.(8) Agents linked to 
human poisoning include both organophosphate (parathion, profenofos, 
chlorpyrifos, Malathion, diazinon) and carbamates (methomyl and aldicarb) 
insecticides. Accidental poisoning may occur due to inhalation while spraying 
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insecticide for crops, while self-poisoning is always by ingestion to commit 
suicide. Large scientific studies suggests that Organophosphate exposure is one 
of the major threat toxicologically that affects both animal and human health 
because of its various toxicities like endocrine toxicity, immunotoxicity, 
neurotoxicity, alterations in cellular oxidation and even genotoxicity. For 
military purposes organophosphorus nerve agents like sarin, tabun were 
developed in Germany during 1940s, but they were not used. Medical 
applications of organophosphates and carbamates include treatment of 
glaucoma, reversal of neuromuscular blockade (neostigmine, pyridostigmine, 
and edrophonium), Alzheimer disease (donepezil, pyridostigmine, tacrine and 
echothiophate), and myasthenia gravis. 
CHEMISTRY: 
 Organophosphates includes various types of molecules with a different 
biological, chemical, and physical properties along with toxicity. Initially 
organophosphates were introduced as substitutes for the organochlorine 
insecticides. Organophosphates are compounds of different volatility, insoluble 
or soluble in water, organic solvents etc. Chemically these compounds are 
derivatives of phosphinic (H3PO2), phosphoric (H3PO4), and phosphorous 
(H3PO3) acids. The compound with significant biological effect have the 
following general formula. 
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Figure 1 STRUCTURE OF ORGANOPHOSPHATE 
Where R1, R2 are hydrogen / alkyl / aryl and others, alkylthio, alkoxy 
and amino groups. R3 is a removable group, eg: halogens, organic or inorganic 
acid(17). Basic characteristics of these compounds is the toxicity profile. 
Depending on the conditions of its molecular structure, various types (chronic, 
subchronic, and acute) of toxicity are differentiated. LD50 is used to 
characterise the acute toxicity.  
Toxicity of organophosphates: 
 Organophosphate toxicity is determined by several factors. Of these, the 
important ones are the route of contact, molecular structure, and its relation 
with the biotransformation and detoxification system in the body. 
Organophosphate compounds are absorbed through inhalation, ingestion, and 
also through integumentary system. The dissemination of Organophosphates is 
variable following absorption. The half-life of the compound is short in blood 
though in some cases it can be several days. OP compounds undergo extensive 
biotransformation in the body in various organs, by concurrent oxidative 
biotransformation at various points in the compound, using cytochrome P450 
complex. Oxidation is the prime mode of metabolism, also there is cleavage by 
13 
 
esterase, and transfer of the parts of OP compounds to Glutathione. 
Organophosphate oxidation produces less or more toxic compounds. Following 
the primary biotransformation process, various conjugation reactions happen 
resulting in excretion of phosphorus containing residue in urine and faeces. 
Some residues may remain in the system for a very long time. 
CHOLINESTERASES: 
 Cholinesterase are a group of enzymes that belong to hydrolases 
dividing the ester bond, to be precise, the esterase subgroup catalysing the 
hydrolytic reaction of esters to acid plus alcohol. Cholinesterase hydrolyse 
choline esters readily than other esterase and it is more specific to 
organophosphates as well as serine. Cholinesterase are subdivided to acetyl 
cholinesterase and butyryl cholinesterase according to their affinity to their 
substrates(18). Acetyl cholinesterase or true cholinesterase has more affinity to 
acetyl-choline comparing to butyryl choline and cleaving acetyl beta 
methylcholine. The activity of acetyl cholinesterase is high in erythrocytes, the 
brain and in neuromuscular junction. Excess of substrate will inhibit the 
acetylcholinesterase enzyme itself. Acetylcholinesterase has different subunits 
and can be divided into different molecular forms. Butyrylcholinesterase, or 
pseudo cholinesterase, a nonspecific cholinesterase, is found in pancreas, 
plasma, and liver and it is synthesised there. Butyrylcholinesterase will not 
metabolise acetyl beta methyl choline and it has more affinity for butyryl 
choline and also propionyl choline when comparing to acetyl choline. But 
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substrate inhibition of cholinesterase is not observed as in acetylcholinesterase. 
There are Butyrylcholinesterase isoenzymes that are 
 
Figure 2 NEUROMUSCULAR JUNCTION 
genetically fixed. Based on the genetic setup some persons may have high or 
low Butyrylcholinesterase activity. Those with genetically reduced 
Butyrylcholinesterase activity are at an increased risk of cholinergic toxicity 
when they have exposure to pesticides or succinylcholine(19, 20). The plasma of 
persons with standard levels of butyrylcholinestease will bind to 
Organophosphates/succinylcholine and hydrolyse them and hence the real dose 
of these penetrating into the tissues will be very low. Both acetylcholinesterase 
and Butyrylcholinesterase differ not only in their enzymatic property but also 
in their physiological action(21). Acetylcholinesterase splits acetylcholine at the 
neuromuscular junction while butyryl cholinesterase action is involved in 
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neuromuscular transmission also, it action is in other detoxification processes 
and lipid metabolism(22). 
METABOLISM OF ORGANOPHOSPHORUS COMPOUNDS 
ABSORPTION 
 Organophosphorus compounds contain phosphoric acid derivatives and 
carbon in their aryl/alkyl groups. These compounds are well absorbed through 
skin, gastrointestinal tract, and lungs. The extent of absorption rest on the 
interaction time involved with the integuments, the lipid affinity of the 
compounds, and presence of organic solvents like toluene/xylene mixed with 
them, emulsifiers in the preparationthatwillease the absorption. Some other 
vital factors involved in absorption include volatility of pesticide, porousness 
of apparel, range of coverage of body surface and personal hygiene of the 
victim. The degree of absorption also differs as the skin of the area involved 
varies. E.g., Parathion is easily absorbed into the skin in scrotum, head and 
neck and axillae, comparing too the skin of arms and hands. The absorption is 
also high through traumatized integument and existence of dermatitis also 
permits more absorption of organophosphorus agents(23). 
DISTRIBUTION AND STORAGE: 
 Once Organophosphorus compounds are absorbed, they accumulate in 
body fat, kidneys, liver, and in salivary glands(24). Phosphorothioates [P=S] like 
parathion, diazinon and bromophos has more lipid affinity than the phosphates 
[P=O] like dichlorvos and hence these are deposited more in body fat and are 
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responsible for protracted intoxication(25) and relapse after apparent clinical 
recovery which are observed with these Organophosphate compounds. 
Organophosphorus compounds are generally lipophilic and hence go through 
blood-brain barrier more readily in many of the patients(23). 
BIOTRANSFORMATION 
 Phosphates [P=O], they are biologically active inhibitors of acetyl-
cholinesterase while Phosphorothioates [P=S] want bio activation to its 
phosphate metabolite (oxon) to turn active biologically (called lethal 
synthesis)(25, 26). Hence the toxidrome of Phosphorothioates are late lest aerial 
oxidation has happened previously to generate the biologically active oxons 
(more toxic). Organophosphorus agents that are not phosphates are converted 
to oxon form by oxidation de-sulfuration facilitated by P450 isoforms, in 
presence of flavin holding monooxygenase enzymes(17). 
ELIMINATION 
 The metabolites of Organophosphorus compounds are eliminated 
usually through urine and smaller extent in exhaled air and in faeces. The 
organophosphates which are not stored in fat are excreted in hours however, 
inhibitory oxons of compounds like chlorpyrifos will remain for days in the 
body, the reason behind is their depot storage in fat(23). 
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MECHANISM OF ACTION 
 
FIGURE 3 ACETYLCHOLINE METABOLISM 
Acetylcholinesterase is the enzyme that causes hydrolytic cleavage of 
acetyl choline to acetic acid and choline. For all pre-ganglionic autonomic 
fibres and post-ganglionic parasympathetic fibres, acetylcholine is the 
neurotransmitter. Acetylcholine is also the neurotransmitter at skeletal muscle 
motor-endplates and inter-neuronal synapses in central nervous system. Action 
potential transmission is mediated by presynaptic release of acetylcholine in the 
inter-neuronal cleft. The organization of synapse is in the way that 
acetylcholine comes in contact with acetylcholinesterase before reaching the 
postsynaptic receptors, which results in postsynaptic excitatory potential and 
hence the propagation of action potential. This event is transient because 
acetylcholine is degraded by acetylcholinesterase. Hence inhibition of 
acetylcholinesterase causes prolongation of cholinergic post-synaptic 
transmission time and hence causes continuous cholinergic overstimulation. 
The Organophosphate agents inhibit the activity of acetylcholinesterase by a 
catalytic reaction wherein the serine-hydroxyl moiety in the active site 
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(esteratic site) of the enzyme is phosphorylated (27, 28). The cleavage of carbon-
enzyme bonds in acetylcholine is completed in a very few micro-seconds. But 
the cleavage of phosphate-enzyme bond needs a long period 
 
Figure 4 Acetylcholine Metabolism 2 
varying from sixty minutes to quite a few weeks depending upon the 
organophosphate agent involved. Spontaneous reactivation of the 
phosphorylated enzyme may occur, but the reactivation rate depends on the 
tissue as well as the prosthetic group which got bound to the enzyme. O-O 
dimethyl phosphorylated acetylcholinesterase gets reactivated spontaneously in 
one day which hence assists recovery from the cholinergic crisis. Reactivation 
of O-O diethyl phosphorylated acetylcholinesterase is considerably 
sluggish(29)(27, 28). The response to oximes for reactivation of inhibited 
cholinesterase declines with time because of “ageing” of the inhibited 
acetylcholinesterase. Ageing of the phosphorylated enzyme is most likely due 
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to loss of one alkoxy or alkyl group, resulting in a more stable compound, 
monoalkyl- or monoalkoxy-phosphoryl acetylcholinesterase. The rapidity of 
ageing of acetylcholinesterase is in the order isopropyl-methyl>dimethyl>di 
isopropyl>diethyl (29). 
 Delayed neurotoxic effect of Organophosphorus compounds is not 
because of acetylcholinesterase inhibition, instead it is due to phosphorylation 
of a particular esteratic enzyme in the neurons(30, 31) called “neurotoxic 
esterase” or neuropathy target esterase (NTE)(32, 33) . The first catalytic step is 
phosphorylation of neuropathy target esterase. The next reaction which is the 
cause for neuropathy is the biotransformation of the phosphorylated-enzyme to 
an aged compound(34).  
 Some other enzymes in the body are also phosphorylated including 
lipases, chymotrypsin, and trypsin by organophosphate compounds. The rate of 
reaction is slow generally with these enzymes. The clinical effects of inhibition 
of these enzymes are not known yet(29). 
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Figure 5 ORGANOPHOSPHATE AGEING 
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MYOPATHIC EFFECTS 
 Muscular weakness following organophosphate poisoning was one of 
the earliest findings discovered by Carey. Necrotic changes is extensive in 
motor endplates(35). The maximal necrosis happens during one to three days 
and recovery features starts at 7th day, and full recovery occurs at two to three 
weeks. OP induced myopathy is distinct from neuropathy that begins 
approximately after 3 weeks when normal muscle strength returns(36). Failure to 
sustain tetanic stimulation was witnessed following OP poisoning in 
investigational animals. When normal muscle sustains tetanic stimulation at 25 
Hz, 50 Hz, 100 Hz, & 200 Hz for ten seconds, 2-4 hours after organophosphate 
poisoning, at 100 Hz the contractions were insufficient, and at 200 Hz it was 
absent. Muscle paresis observed in the OP poisoning patients after an apparent 
recovery from the acute crisis due to cholinergic activation but before the onset 
of polyneuropathy is identified as intermediate syndrome(37). High 
concentration of acetylcholine at the motor endplates causing prolonged 
depolarisation is due to prolonged change in ion flux of junctional membrane 
and it is considered to be the cause of muscle necrosis(38). The severity of 
myopathy correlates with the degree and duration of acetylcholinesterase 
inhibition which initiates a neutrally mediated events, causing increased 
neurotransmitter release and antidromic activity(39). Dissolution of the Z bands 
of sarcoplasmic reticulum suggests disturbances in the Calcium flux following 
organophosphate poisoning(35). 
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RESPIRATORY DISORDERS 
 Organophosphate compounds cause a CNS depression of respiration in 
animals. The important findings are swiftly advancing bradypnea and resulting 
in apnea because of reduced respiratory effort. There is evidence to suggest a 
fall in central inspiratory drive due to OP poisoning(40). There is also some 
studies to suggest an intact respiratory muscles activity following OP poisoning 
but having respiratory failure(41). 
HEPATOLOGICAL DISORDERS 
 The bio-activation and metabolism of Organophosphorus molecules 
happen in liver. They are excreted chiefly through renal system(42). The profile 
of hepatic transaminases, antioxidant-enzymes, and trace elements are very 
much affected following organophosphate poisoning(43). The histopathological 
findings in human liver after an acute OP poisoning are, centrilobular necrosis, 
congestion, fatty changes, and sinusoidal dilatation(44).  
CARDIOVASCULAR DISORDERS 
 Myocardial necrosis following Organophosphate poisoning was reported 
by Povoa et al(45). Elevation in creatinine kinase and lactate dehydrogenase 
following organophosphate poisoning(46). Sinus tachycardia, hypertension, 
sinus bradycardia, hypotension, impaired force of contraction, myocardial 
necrosis are the cardiac manifestations(47). Ecg changes are Prolonged QT 
interval, low amplitude T waves, ectopic beats, ST segment elevation, and PR 
interval prolongation(48).  
23 
 
NERVOUS SYSTEM DISORDERS 
 In experimental rats, necrosis of neurons has been demonstrated in sub-
cortical and cortical areas following acute large doses of organophosphate 
poisoning(47). There are several neurological disorders reported in acute or 
chronic organophosphate poisoning(23). These syndromes vary widely, which 
include parkinsonian signs, pseudo bulbar signs, OP induced delayed 
peripheral neuropathy, changes in libido, affect and memory, psychiatric and a 
slowly progressive neuro-psychological disturbances (chronic organophosphate 
induced neuropsychiatric disorder) and cerebellar syndrome(49). 
HORMONAL IMBALANCE 
 Several adverse outcomes regarding fertility due to sex hormone 
imbalance because of pesticide exposure has been published in late 20th century 
including feta death, congenital malformations, and intrauterine growth 
restriction(50). Since a large exposure to pesticides occur when living in rural 
area, it is a potential risk factor for infertility(51). 
ESOPHAGEAL EFFECTS 
 Esophago-gastroscopy immediately following organophosphate 
poisoning revealed oedema, circumferential hyperaemia, and punctate bleeding 
throughout the esophagus(23). 
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RENAL IMPAIRMENT 
 Many studies and case reports have been documented regarding 
organophosphate poisoning and the causation of acute renal failure. It is also 
shown that prolonged exposure to pesticides lead to chronic kidney disease(23) 
ANTIOXIDANT STATUS PLUS OXIDATIVE STRESS 
 Enhanced lipid peroxidation, elevated oxidative stress and reduced 
glutathione levels have been shown in Organophosphate poisoning(52, 53). 
ORGANOPHOSPHATE POISONING AND PREGNANCY 
 OP poisoning in pregnancy has caused pre natal and post natal death and 
congenital abnormalities in experimental animals. The congenital abnormalities 
include, limb defects, polydactyly, hydroureter, vertebral deformities, and cleft 
palate(29). During 3rd month of pregnancy, following organophosphate 
poisoning, the fetus was aborted in one case as continuation of pregnancy was 
considered harmful(54, 55). But successful management of OP poisoning during 
2nd and 3rd trimester had resulted in term deliveries and normal healthy 
babies(55). 
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CLINICAL MANIFESTATIONS 
 
 
Figure 5 MUSCARINIC SIGNS OF OP POISONING 
  
Cholinergic manifestations can be summarised under three categories 
namely, muscarinic, nicotinic, and central. The symptoms appear varying in 
combination. The intensity and onset time of symptoms depends on the mode 
of poisoning and composition of the poison. When the ingestion is massive 
then the symptoms arise within minutes. Most of the times the symptoms arise 
within 30 minutes of exposure and in less than 12 hours. The usual cause of 
death and the most serious manifestation is respiratory failure which results 
from paresis of muscles of respiration, central depression of respiratory drive, 
aggravated with bronchospasm and excessive airway secretions. Impaired 
consciousness and vomiting also leads to aspiration pneumonitis. Increased 
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cholinergic activation causes bradycardia and may lead to heart blocks. The 
`muscarinic signs are easily remembered as SLUDGE/BBB – Salivation, 
Lacrimation, Urination, Defecation, Gastric emesis, Bronchorrhea, 
Bronchospasm, and Bradycardia or as DUMBELS – Defecation, Urination, 
Miosis, Bronchorrhea/Bradycardia, Emesis, Lacrimation, and Salivation (56). A 
few case reports suggest that there is signs of myocardial ischemia like elevated 
troponin or ECG changes in Organophosphorus poisoning (57, 58). The levels of 
troponin peaks on presentation in most of the cases and the risk is more in older 
patients but is very low in mild poisoning. 
INTERMEDIATE SYNDROME 
 The onset is acute in IMS, and is usually manifests 24 to 96 hours after 
poisoning, affecting the patients who are conscious without cholinergic features 
or fasciculations. The presentation of this syndrome is paresis affecting 
preferentially the proximal group of muscles in limbs and flexors of neck(59). 
Musculature that are innervated by cranial nerves III to VII and X are also 
involved in various combinations. This syndrome increases the risk of death, 
because of the respiratory arrest which unless recognised timely and treated 
promptly (60). These patients are usually conscious, and they show marked 
anxiety, restlessness and sweating because of progressive hypoxia. The most 
important feature is significant neck muscle weakness and the victims are not 
able to lift the head from pillows. They also show more weakness in hip flexion 
and shoulder abduction. These musculature do not have fasciculations and the 
stretch reflexes are reduced or often absent(61). No sensory impairment is noted 
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in intermediate syndrome. Intermediate syndrome is likely to result from the 
post synaptic neuromuscular dysfunction. The risk factors for this syndrome 
includes highly fat soluble Organophosphorus agent and also linked to 
inadequate doses of oximes(62). It is not usually described in carbamate 
poisoning. With adequate supportive care, prolonged mechanical ventilation, 
most people recover completely from this neurological dysfunction within 2 to 
3 weeks. Clinical deterioration and improvement correlates with RBC 
cholinesterase levels. 
BOX 1 DIFFERENCES BETWEEN IMS AND OPIDN 
 IMS OPIDN 
Time of onset One to four days Two to three weeks 
Site of weakness Proximal Distal 
Neck muscles + - 
Limb muscles + - 
Cranial nerves + - 
Ventilatory muscles + - 
Electromyogram Tetanic fade Denervation 
Organophosphorus 
agents 
Fenthion 
Monochrotophos 
Methmidophos, 
Chlorpyrifos 
Recovery 4-18 days 6-12 months 
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DELAYED AND LONG-TERM NEUROPATHOLOGY 
 IT occurs one to three weeks after ingestion of Organophosphorus 
agents like chlorpyrifos (63, 64). Carbamates are very rarely cause development 
of delayed peripheral neuropathy (65, 66). The mechanism of causation of 
delayed neuropathy involves inhibition of neuropathy target esterase NTE 
rather than RBC cholinesterase (67). The patients who are affected usually 
presents with glove and stocking paraesthesia subsequently resulting in 
symmetrical motor polyneuropathy which manifests by flaccid weakness of 
lower extremities which may ascend to affect upper extremity. Sensory 
involvement is usually minimal. Delayed neuropathy usually involves distal 
group of muscles but in severe poisoning proximal groups may also get 
involved (68). Electromyogram and nerve conduction studies show reduced 
firing of motor conduction units (69). Histopathological analysis of the involved 
peripheral nerves show wallerian degeneration of large distal axons (70) 
Figure 6 AGENTS ASSOCIATED WITH DELAYED PERIPHERAL 
NEUROPATHY 
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DIAGNOSIS 
Organophosphate poisoning is usually diagnosed on the basis of clinical 
scenario. If known ingestion or exposure to OP agent is not evident, the clinical 
signs of cholinergic crisis may show the likelihood of organophosphate 
poisoning. Many organophosphate compounds have a characteristic garlic like 
or petroleum odour which is useful in making the diagnosis. Because of the 
significant variability in toxicity, effort must be made to precisely identify the 
agent involved. It is imperative to find out if a dimethyl or diethyl poison is 
involved. The duration of toxidrome and the therapeutic window during which 
the treatment with an oxime is likely to be effective are markedly different 
between these two groups of organophosphate compounds. Dimethyl 
compounds undergo rapid ageing, hence the therapy with oxime is critical; 
diethyl compounds exhibits delayed toxicity and hence require a prolonged 
treatment(13). Clinical signs of Organophosphorus toxicity express when the 
cholinesterase values drop to less than 75%. It will be < 10% in clinically overt 
poisoning (23, 71, 72). If there is a doubt whether an organophosphate is ingested 
or not, 1 mg of atropine in adults or 0.01 to 0.02 mg/kg of atropine in children 
can be tried. Following atropine injection if there is no signs and symptoms of 
anticholinergic effects then it suggests the diagnosis of poisoning with 
acetylcholinesterase inhibitor. Bardin’s classification is used for grading the 
patient according to clinical findings(73) 
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BOX 2 BARDIN’S CLASSIFICATION OF DEGREE OF 
ORGANOPHOSPHATE POISONING 
Bardin’s classification of degree of Organophosphate poisoning(73) 
Grade 0 No clinical manifestations 
Grade 1 
Hyper secretion, fasciculations, 
Conscious 
Grade 2 
Grade 1 +unconsciousness, 
hypotension 
Grade 3 
Grade 2 + abnormal chest x-ray, 
Stupor,  
pO2less than 10 mm Hg 
 
LABORATORY ABNORMALITIES 
 Measurement of RBC cholinesterase activity is a measure of level of 
toxicity. Sequential measurement of cholinesterase levels also helps in 
assessment of adequacy of oxime therapy in regeneration of cholinesterase 
levels. Plasma cholinesterase estimation is easily done and hence employed in 
most of the laboratories but it does not correlate well with the severity of 
poisoning like RBC cholinesterase(74). Several liver enzyme abnormalities are 
noted in OP poisoning including elevations in ALT, AST, and ALP. Serum 
amylase is also noted to get elevated because of excessive cholinergic 
stimulation of pancreas. Creatine phosphokinase get elevated in OP poisoning 
during the acute phase and also during the intermediate syndrome. Few studies 
have reported elevation in CPK-MB and troponin levels indicating myocardial 
necrosis in organophosphate poisoning. 
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MANAGEMENT 
 Severe organophosphate intoxication is a medical emergency. The 
management starts with patent airway, breathing, & circulation. O2 must be 
provided at the earliest. The victim is kept in left-lateral position along with 
extended neck. Inorder to keep the airway patent and reduce the risk of 
aspiration this position is useful. It also slows the gastric transit and hence 
decreases absorption of the poison(75). Stomach wash is effective if given 
within thirty minutes of poisoning, and if it is delayed it can also be done on 
admission after confirming that the airway is secure. Induction of vomiting 
with emetics like ipecacuanha must be avoided, because unconsciousness can 
rapidly set-in before vomiting(76). In patients with topical exposure there is 
potential risk for dermal absorption and hence aggressive decontamination, 
complete removal of contaminated clothes from the body and complete 
cleansing of the involved parts must be done. Patients’ garments and stuffs that 
are contaminated must be cast-off because it can absorb the OP compounds and 
re-exposure to patient can occur even after washing. Health care workers 
should take necessary precautions to avoid accidental exposure to such 
contaminated clothing and also providing treatment in well ventilated areas (77-
79). Moderate to severely intoxicated patients having depressed sensorium need 
100% O2 and endotracheal intubation for mechanical ventilation. Patients who 
appear to have mild poisoning may also quickly develop failure of respiration 
due to nicotinic receptor mediated diaphragmatic weakness, CNS respiratory 
center depression, bronchospasm and copious secretions. So these patients may 
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also be considered for an early intubation. Patients with cholinergic toxicity 
due to organophosphate poisoning are treated with atropine and oxime therapy. 
ATROPINE 
 Atropine acts like a physiological antidote, competes with the 
acetylcholine at the muscarinic receptors, thus preventing cholinergic 
activation. In patients with moderate to severe poisoning, atropine is initiated in 
a dose of 2mg to 5mg intravenously for adults repeated at intervals of 5 to 10 
minutes and 0.02 to 0.05mg per kg for pediatric age group & repeated at 
intervals of 10 to 30 minutes(80). If there is no improvement the dosage is 
doubled every 3 to 5 minutes till pulmonary muscarinic signs reduces. There is 
no need for providing oxygen prior to administration of atropine (81). The 
dosing of atropine must be increased or decreased to the point of clearing the 
airway secretions and relief of Broncho-
constriction. Tachycardia and Mydriasis are not 
markers appropriate for therapeutic improvement, 
because they may indicate hypovolemia, 
continued hypoxia, or sympathetic stimulation(82). 
Continuous observation is required to ensure 
maintenance of adequate atropinisation. A heart 
rate of exceeding 140 beats per minute must be 
avoided. ST segment changes in Ecg can be 
caused by large doses of atropine, which can be 
Figure 7 ATROPINE SULFATE 
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reverted with propranolol without the need for reducing the dosage of 
atropine(83).  
OXIMES 
  Oximes compounds that can re-activate the phosphorylated 
acetylcholinesterase more quickly than the spontaneous re-activation by 
hydrolysis. They have three main actions(84): (1) transforming the OP agent into 
a non-reactive compound by a direct reaction (2) protecting cholinesterase from 
sustained inhibition by a 
transient reaction (3) re-
activation of the alkyl-
phosphorylated AchE to 
release the active enzyme. 
There are plenty of oximes 
studied to date, but molecules 
with clinical utility can be subdivided into two classes namely, mono-
pyridinium and bis-pyridinium. The only used mono-pyridinium is Pralidoxime 
(P2AM) whereas other bis-pyridinium compounds include obidoxime, 
trimedoxime, and asoxime. There is no universal agreement on which is the 
most effective oxime and its dosing regimen. 
Figure 8 PRALIDOXIME 
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Figure 9 TYPES OF OXIMES 
WHO commends that oximes should be administered to those patients 
who require atropine(85). Inorder to maintain the therapeutic concentration, a 
loading-dose should be given at first followed by a continuous infusion of 
Oximes. The loading-dose must not be administered as a iv bolus because it 
can cause vomiting (may lead to aspiration), diastolic-hypertension and 
tachycardia(86). The bolus dose is given as 2 grams iv followed by 500 mg/ hr 
as infusion continuously till clinical progress is noted or 30 mg per kg body-
weight as bolus iv for 4 to 6 hrs. Or 8 – 10 mg/kg/hr IV till complete recovery. 
For patients who develop intermediate syndrome, Pralidoxime is given for 
longer periods till they are weaned off from mechanical ventilation. 
Pralidoxime may also be given as s.c or i.m. In view of very short elimination 
half-life 1.2 hours following an IV injection, continuous infusion is found to be 
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better than bolus therapy to maintain therapeutic concentrations. The maximal 
recommended dose of Pralidoxime is 12 grams in 24 hours for adults. Huge 
doses of P2AM and other oximes themselves can lead to neuro-muscular 
blockage and inhibition of acetylcholinesterase. Pralidoxime must be given as 
soon as possible in organophosphate poisoning, atleast within 24-36 hours, for 
the reason that reactivation of acetylcholinesterase is primarily reliant on life 
span of RBC when the enzyme ages and thus regeneration may take weeks. 
P2AM is not equally efficacious to every organophosphate compound. The 
effects of diethyl compounds are antagonised more efficiently than that of 
dimethyl/ dimethoxy-compounds(29).  
BENZODIAZEPINES 
 Organophosphate poisoning patients commonly develop restless 
delirium. It could be pesticide itself, atropine toxicity, and alcoholic 
intoxication along with poisoning and other medical complications. Restless 
patients may improve on treatment with diazepam(87). Studies done in animals 
show that diazepam decreases neuronal damage and precludes respiratory 
failure in OP poisoning however human trials are few(87). Prophylactic 
diazepam had shown to reduce the incidence of neurocognitive dysfunction 
after OP poisoning (88, 89). There is no evidence that phenytoin has effect on 
organophosphate compound induced seizures and hence it is not recommended. 
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Figure 10 SUMMARY OF OPC POISONING 
 
OTHER THERAPIES UNDER RESEARCH: 
 Magnesium sulphate acts by blocking ligand-gated calcium channels at 
the neuro-muscular junction and hence results in deprived acetylcholine release 
from presynaptic terminals, resulting in improved functioning of 
neuromuscular junctions and prevents activation of NMDA receptors and 
overstimulation of CNS. 
 Sodium bicarbonate is used in Iran and Brazil for treatment of Opc 
poisoning instead of oximes. Escalation in pH of blood upto 7.45 – 7.55 has 
resulted in better result in dogs by an unknown mechanism(90). 
 Clonidine is an agonist of alpha 2-adrenergic receptor that reduces 
acetylcholine synthesis and also its release from pre-synaptic terminals. 
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Experiments in animals has shown better results when treating with clonidine 
along with atropine, however the studies in human being are undergoing. 
 When the organophosphate compound is removed from blood it can 
allow better action of other treatments. The part of hemofiltration and 
haemodialysis are not clear in management of OP poisoning. The benefit of 
hemofiltration has been shown in a research done in China following poisoning 
with dichlorvos, an OP agent with poor lipid solubility and thus having small 
volume of distribution. 
 In a study conducted in China, Fresh frozen plasma was used along with 
the traditional treatment for OP poisoning. It is observed that for every two 
bags of FFP given there is an increase of 461.7+/- 1421.1 IU/L in the levels of 
butyrylcholinestease. Since OP agents may get released from the fat tissue 
slowly for a prolonged period, FFP doses must be repeated till 
Butyrylcholinesterase goes up to a desirable level(91). 
 PON1 (Paraoxonase) is an important enzyme in the metabolism of 
organophosphate agents. Though hydrolysis PON1 can deactivate certain 
organophosphate agents. PON1 hydrolyses only the metabolic end-products of 
the organophosphate agents and not the parent compounds(92). There are PON1 
polymorphisms which causes different individuals to have variable 
susceptibility to individual OP agents. If the PON1 concentration is higher it 
offers better protection to the individual. Further data regarding PON1 are 
under research(93). 
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STATISTICS 
 
SEX RATIO 
Table 3 SEX RATIO 
SEX 
No.of respondents 
(n=50) 
Percentage 
(100%) 
Male 37 74.0 
Female 13 26.0 
  
 In this study with a total participants of 50 patients, 37 of them are male 
(74%) and 13 of them are female (26%). 
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AGE WISE DISTRIBUTION 
Table 4 AGE WISE DISTRIBUTION 
Age  
No.of respondents 
(n=50) 
Percentage 
(100%) 
20 to 30yrs 31 62.0 
31 to 40yrs 9 18.0 
41 to 50yrs 5 10.0 
51 to 60yrs 5 10.0 
 
 In this study, the total number of participants include 50 patients, and 
among them 31 of them (62%) belong to 20 to 30 years age group. 
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TYPES OF COMPOUND INGESTED 
Table 5 TYPES OF COMPOUND INGESTED 
COMPOUND 
No.of respondents 
(n=50) 
Percentage 
(100%) 
CARBOFURAN 3% 3 6.0 
CHLORPYRIFOS 20% 8 16.0 
DIMETHOATE 30% 5 10.0 
FOLLIDOL 9 18.0 
PROFENOFOS 20% 1 2.0 
PROFENOFOS 40% 1 2.0 
PROFENOFOS 50% 19 38.0 
TRIZOPHOS 4 8.0 
 
 In this study group the commonest compound ingested is 50% 
Profenofos (19 patients), followed by Follidol (9 patients), Chlorpyrifos 20% (8 
patients), and dimethoate 30% (5 patients). 
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Table 6 Ingested with Alcohol or not? 
ALCOHOL 
No.of respondents 
(n=50) 
Percentage 
(100%) 
No 15 30.0 
Yes 35 70.0 
  
 In this study, out of 50 patients, 35 patients (70%) consumed 
Organophosphate compound after mixing with alcohol. 
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DISTRIBUTION ACCORDING TO DURATION BETWEEN INGESTION 
OF ORGANOPHOSPHATES AND PRESENTATION TO ED 
Table 7 Time interval between ingestion of poison and presentation to 
hospital 
TIME INTERVAL 
(In hours) 
No.of respondents 
(n=50) 
Percentage 
(100%) 
1 7 14.0 
2 16 32.0 
3 12 24.0 
4 8 16.0 
5 4 8.0 
6 3 6.0 
 
 Most of the patients (32%) presented to the hospital within 2 hours of 
poisoning, 24% within 3 hours, 16% within 4 hours, and 14% within 1 hour. 
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TABLE 8 DISTRIBUTION ACCORDING TO PRESENCE OF 
SYMPTOMS 
 
Except one patient all of the patients in the study group presented with 
symptoms of organophosphate poisoning with classical cholinergic features. 
DISTRIBUTION ACCORDING TO SEVERITY BY BARDIN’S 
CLASSIFICATION 
Table 9 BARDIN’S CLASSIFICATION 
BARDIN 
No.of respondents 
(n=50) 
Percentage 
(100%) 
1 11 22.0 
2 20 40.0 
3 19 38.0 
 
 Out if 50 patients in the study, 20 patients presented in grade II severity 
according to Bardin classification and 19 patients presented in Bardin grade III 
severity, And remaining 11 patients presented in Bardin severity grade I. 
SYMPTOMS 
No.of respondents 
(n=50) 
Percentage 
(100%) 
No 1 2.0 
Yes 49 98.0 
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DISTRIBUTION ACCORDING TO VENTILATOR SUPPORT 
REQUIREMENT 
TABLE 10 VENTILATOR SUPPORT REQUIREMENT 
VENTILATOR 
No.of respondents 
(n=50) 
Percentage 
(100%) 
No 21 42.0 
Yes 29 58.0 
  
 In this study out of 50 patients, 29 patients were ventilated for 
respiratory failure and 21 patients did not require ventilator support. 
 
DISTRIBUTION ACCORDING TO THERAPEUTIC END POINT 
Table 11 ACCORDING TO THERAPEUTIC END POINT 
OUTCOME 
No.of respondents 
(n=50) 
Percentage 
(100%) 
Death 21 42.0 
Live 29 58.0 
 
 In this study, 29 patients had a successful therapeutic end point, and 21 
patients expired inspite of appropriate treatment. 
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DISTRIBUTION ACCORDING TO TROPONIN I RESULT 
Table 12 TROPONIN I RESULT 
TROP I 
No.of respondents 
(n=50) 
Percentage 
(100%) 
Negative 27 54.0 
Positive 23 46.0 
 
 In this study of 50 patients, 23 patients had troponin I positivity and 27 
patients had troponin I negative. 
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DESCRIPTIVE STATISTICS 
Table 13 DESCRIPTIVE STATISTICS AGE, QUANTIITY, and TIME 
INTERVAL 
 
N Min. Max Mean S.D 
AGE 
(IN 
YEARS) 
50 20 60 32.20 11.416 
QUANTITY 
(IN ML) 
50 50 250 145.20 61.053 
TIME INT 
(IN 
HOURS) 
50 1 6 2.90 1.389 
 
 In this study group, the mean age of presentation is 32.2 years with a 
standard deviation of 11.416. The mean quantity of poison ingested is 145.20 
ml with a standard deviation of 61.053. The mean time interval of presentation 
is 2.90 hours with a standard deviation of 1.389. 
POSITIVE NEGATIVE
TROPONIN I 23 27
21
22
23
24
25
26
27
28
TROPONIN I
TROPONIN I
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ANALYSIS OF LIVER ENZYMES AND AMYLASE 
Table 14 DESCRIPTIVE STATISTICS LIVER ENZYMES, AMYLASE 
 N Min. Max Mean S.D 
AST 50 20 220 113.48 50.287 
ALT 50 18 220 109.62 50.004 
ALP 50 48 362 165.96 82.646 
AMYLASE 50 34 360 160.96 93.453 
 
 
 
 The mean values of AST-113.48 IU/L, ALT-109.62 IU/L, ALP- 165.96 
IU/L, and Amylase- 160.96 IU/L is noted among the poisoning patients in this 
study. 
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ANALYSIS OF SERUM ELECTROLYTES 
Table 15 DESCRIPTIVE STATISTICS SERUM ELECTROLYTES 
 Min. Max Mean S.D 
SODIUM 
(IN MEQ/L) 
126 144 134.90 3.370 
POTASSIUM 
(IN MEQ/L) 
2.60 3.80 3.2140 .22769 
 
ANALYSIS OF CREATINE PHOSPHOKINASE 
Table 16 DESCRIPTIVE STATISTICS CPK, CPK MB 
 Min. Max Mean S.D 
CPK 
(IU/L) 
30 3738 802.38 955.396 
CPK-MB 
(IU/L) 
15 758 191.76 207.497 
 
CHI-SQUARE TEST TO COMPARE THE OUTCOMES WITH 
DIFFERENT AGE GROUPS 
Table 17 THE OUTCOMES WITH DIFFERENT AGE GROUPS 
AGE 
Death Live Total 
Statistical 
inference (n=21) (100%) (n=29) (100%) (n=50) (100%) 
20 to 30yrs 15 71.4% 16 55.2% 31 62.0% 
X2=1.981 
Df=3 
.576>0.05 
Not 
Significant 
31 to 40yrs 2 9.5% 7 24.1% 9 18.0% 
41 to 50yrs 2 9.5% 3 10.3% 5 10.0% 
51 to 60yrs 2 9.5% 3 10.3% 5 10.0% 
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 There is no statistical significance when outcome is compared with 
different age groups of patients in this study group. 
CHI-SQUARE TEST TO COMPARE THE OUTCOMES WITH SEX OF 
PATIENTS 
Table 18 OUTCOMES WITH SEX OF PATIENTS 
SEX 
Death Live Total Statistical 
inference (n=21) (100%) (n=29) (100%) (n=50) (100%) 
Male 14 66.7% 23 79.3% 37 74.0% 
X2=1.012 
Df=1 
.314>0.05 
Not 
Significant 
Female 7 33.3% 6 20.7% 13 26.0% 
 
 There is no statistical significance when outcome is compared with sex 
of the individuals in the study. 
TO COMPARE THE OUTCOMES WITH COMPOUNDS BY CHI-SQUARE 
TEST 
TABLE 19 OUTCOMES WITH COMPOUNDS 
COMPOUND 
Death Live Total 
Statistical 
inference 
(n=21
) 
(100%
) 
(n=29
) 
(100%
) 
(n=50
) 
(100%
) 
CARBOFURAN 
3% 
1 4.8% 2 6.9% 3 6.0% 
X2=8.865 
Df=7 
.262>0.05 
Not 
Significant 
CHLORPYRIFO
S 20% 
2 9.5% 6 20.7% 8 16.0% 
DIMETHOATE 
30% 
0 .0% 5 17.2% 5 10.0% 
FOLLIDOL 4 19.0% 5 17.2% 9 18.0% 
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PROFENOFOS 
20% 
1 4.8% 0 .0% 1 2.0% 
PROFENOFOS 
40% 
0 .0% 1 3.4% 1 2.0% 
PROFENOFOS 
50% 
11 52.4% 8 27.6% 19 38.0% 
TRIZOPHOS 2 9.5% 2 6.9% 4 8.0% 
 
 
Using Chi-square test the overall outcome is compared with separate 
compounds involved in poisoning. Though maximal negative outcome is 
associated with profenofos 50%, the result is not statistically significant. 
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Table 20 ALCOHOL ALONG WITH OP COMPOUND 
ALCOHOL 
Death Live Total 
Statistical 
inference 
(n=21) (100%) (n=29) (100%) (n=50) (100%) 
No 5 23.8% 10 34.5% 15 30.0% 
X2=.661 
Df=1 
.416>0.05 
Not 
Significant 
Yes 16 76.2% 19 65.5% 35 70.0% 
 
 On comparing the outcome of the patient with mixing of alcohol with 
the poison before ingestion, there is no statistically significance noted. 
CHI-SQUARE TEST TO COMPARE THE OUTCOME WITH 
VENTILATORY SUPPORT REQUIREMENT 
Table 21 OUTCOME WITH VENTILATORY SUPPORT 
REQUIREMENT 
VENTILATOR 
Death Live Total 
Statistical 
inference 
(n=21) (100%) (n=29) (100%) (n=50) (100%) 
No 3 14.3% 18 62.1% 21 42.0% X
2=11.416 
Df=1 
.001<0.05 
Significant Yes 18 85.7% 11 37.9% 29 58.0% 
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 Comparing the outcome with the requirement for Ventilatory support 
following organophosphate poisoning has high statistical significance. 
CHI-SQUARE TEST TO COMPARE THE OUTCOME WITH TROPONIN I 
Table 22 COMPARE THE OUTCOME WITH TROPONIN I 
TROP I 
Death Live Total 
Statistical 
inference 
(n=21) (100%) (n=29) (100%) (n=50) (100%) 
Negative 0 .0% 27 93.1% 27 54.0% 
X2=42.504 
Df=1 
.000<0.05 
Significant 
Positive 21 100.0% 2 6.9% 23 46.0% 
 
 In the study group, there is high statistical significance on comparing 
outcome of the patient with Troponin I. Most of the patients who had Troponin 
I positive had a negative outcome. 
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T – TEST TO ASSESS STATISTICAL SIGNIFICANCE OF VARIAOUS 
PARAMETERS 
AGE Mean S.D 
Statistical inference 
Live (n=29) 32.90 11.040 
T=.503 Df=48 
.617>0.05 
Not significant 
Death (n=21) 31.24 12.124 
 
Table 23 AGE WITH OUTCOME 
 
The mean age of patients who had successful outcome is 32.90 and 
mean age of patients with negative outcome is 31.24. There is no statistical 
significance using age as a predictor of outcome 
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Table 24 QUANTITY WITH OUTCOME 
QUANTITY Mean S.D Statistical inference 
Live (n=29) 143.79 61.086 T=.190 Df=48 
.850>0.05 
Not significant 
 Death (n=21) 147.14 62.461 
 
 The mean quantity of poison ingested among the patients who survived 
is 143.79 ml and the mean quantity of poison ingested among patients who 
expired is 147.14 ml. There is no statistical significance noted using quantity of 
poison ingested as a predictor of outcome. 
Table 25 TIME INTERVAL WITH OUTCOME 
TIME INT Mean S.D Statistical inference 
Live (n=29) 2.45 1.152 T=-2.900 Df=48  
.006<0.05 
Significant 
 Death (n=21) 3.52 1.470 
 
 The average time interval between ingestion of organophosphate and 
presentation to emergency department for a successful outcome is 2.45 hours 
and a negative outcome is 3.52 hours. It is statistically significant and hence 
duration between ingestion of poison and admission to hospital can be used as 
a predictor of outcome. 
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Table 26 ENZYMES WITH OUTCOME 
AST Mean S.D Statistical inference 
Live (n=29) 102.24 50.026 
T=-1.906 Df=48 
.063>0.05 
Not significant 
 
Death (n=21) 129.00 47.494 
ALT Mean S.D Statistical inference 
Live (n=29) 93.31 50.985 
T=-2.909 Df=48 
.005<0.05 
 Significant 
 
Death (n=21) 132.14 39.603 
ALP Mean S.D Statistical inference 
Live (n=29) 157.90 76.705 
T=-.808 Df=48 
.423>0.05 
Not significant 
 
Death (n=21) 177.10 90.954 
AMYLASE Mean S.D Statistical inference 
Live (n=29) 140.59 84.798 
T=-1.856 Df=48 
.070>0.05 
Not significant 
 
Death (n=21) 189.10 99.484 
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 The mean AST in patients who survived is 102.24 and 129.00 in patients 
who expired. Since p value is >0.05 it is not statistically significant to predict 
outcome. 
 The mean ALT in patients who survived is 93.31 and it is 132.14 in 
patients who expired. Since p value is <0.05 it is statistically significant to 
predict outcome. 
 The mean Amylase in patients who survived is 140.59 and it is 189.10 
in patients who expires. Since p value is >0.05 it is not statistically significant 
to predict outcome. 
Table 27 ELECTROLYTES WITH OUTCOME 
SODIUM Mean S.D Statistical inference 
Live (n=29) 135.41 3.123 T=1.275 Df=48 
.208>0.05 
Not significant 
 Death (n=21) 134.19 3.642 
POTASSIUM Mean S.D Statistical inference 
Live (n=29) 3.2690 .23468 T=2.072 Df=48 
.044<0.05 
Significant 
 Death (n=21) 3.1381 .19869 
 
 The mean Serum Sodium in patients who survived is 135.41 and in 
patients who expired is 134.19. The p value is >0.05 and hence it is not 
statistically significant and thus cannot be used to predict outcome. 
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  The mean serum potassium is 3.269 in patients who survived and it is 
3.1381 in patients who expired. Since the P value is <0.05 it is statistically 
significant and hence can be used as a predictor of outcome. 
Table 28 SchE with outcome 
S.AchE Mean S.D Statistical inference 
Live (n=29) 2357.34 2242.477 
T=3.096 Df=48 
.003<0.05 
Significant 
Death (n=21) 821.00 399.836 
  
 The mean serum cholinesterase in patients who survived is 2357.34 and 
in those patients who expired it is 821.00 and it gives a P value of <0.05. It is 
statistically significant to be used as a predictor of outcome. 
Table 29 CPK & CPK MB with outcome 
CPK Mean S.D Statistical inference 
Live (n=29) 444.76 621.248  
T=-3.436 Df=48 
.001<0.05 
Significant 
 
Death (n=21) 1296.24 1120.022 
CPK-MB Mean S.D Statistical inference 
Live (n=29) 81.72 93.538  
T=-5.613 Df=48 
.000<0.05 
Significant 
 
Death (n=21) 343.71 226.792 
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  The mean CPK for the patients who survived is 444.76 and for the 
patients who expired it is 1296.24. The p value is <0.05 and it is statistically 
significant and thus can be used as a predictor of outcome.  
  The mean CPK MB for the patients who survived is 81.72 and for the 
patients who expired it is 343.71. The p value is <0.05 and it is statistically 
significant and thus can be used as a predictor of outcome. 
 The study group 50 patients are classified into 4 groups depending on 
the serum cholinesterase levels.  
S. AchE activity 
No.of respondents 
(n=50) 
Percentage 
(100%) 
< 10% 9 18.0 
10 - 20% 15 30.0 
20 – 50% 15 30.0 
> 50% 11 22.0 
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TABLE 30 SCHE ACTIVITY AND OUTCOME 
S. AchE  
activity 
OUTCOME 
Statistical  
inference 
Death Live Total 
(n=21) (100%) (n=29) (100%) (n=50) (100%) 
Group 1 
<10% 
6 28.6% 3 10.3% 9 18.0% 
X2=11.138 Df=3 
.011<0.05 
Significant 
Group 2 
10-20% 
7 33.3% 8 27.6% 15 30.0% 
Group 3 
20 – 50% 
8 38.1% 7 24.1% 15 30.0% 
Group 4 
>50% 
0 .0% 11 37.9% 11 22.0% 
 
 According to the serum cholinesterase levels, the study patients are 
categorised into 4 groups, Group 1 having the lowest enzyme activity of < 10% 
and group 5 having an enzyme activity of > 50 %. Most of the patients having 
enzyme activity < 10 % had a negative outcome and those who had > 50% 
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enzyme activity had a successful outcome and it is statistically significant. 
Thus Cholinesterase enzyme activity can be used as a predictor of outcome. 
 
ANALYSIS OF VARIATIONS IN PARAMETERS COMPARING WITH 
THE COMPOUNDS USING ONEWAY ANOVA 
Table 31 VARIATIONS IN PARAMETERS COMPARING WITH THE 
COMPOUNDS 
AST Mean S.D Statistical inference 
CARBOFURAN 3% (n=3) 87.33 86.731 
F=.968 
.467>0.05 
Not significant 
CHLORPYRIFOS 20% (n=8) 127.25 20.865 
DIMETHOATE 30% (n=5) 108.60 61.329 
FOLLIDOL (n=9) 125.11 39.397 
PROFENOFOS 20% (n=1) 107.00 . 
profenofos 40% (n=1) 120.00 . 
PROFENOFOS 50% (n=19) 118.95 55.070 
TRIZOPHOS (n=4) 59.50 46.737 
ALT Mean S.D Statistical inference 
CARBOFURAN 3% (n=3) 76.00 49.960 F=1.087 
.389>0.05 CHLORPYRIFOS 20% (n=8) 124.50 27.034 
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DIMETHOATE 30% (n=5) 88.40 42.341 Not significant 
FOLLIDOL (n=9) 113.89 35.364 
PROFENOFOS 20% (n=1) 82.00 . 
profenofos 40% (n=1) 18.00 . 
PROFENOFOS 50% (n=19) 119.68 54.350 
TRIZOPHOS (n=4) 104.00 88.095 
ALP Mean S.D Statistical inference 
CARBOFURAN 3% (n=3) 99.33 8.327 
F=2.782 
.018<0.05 
significant 
CHLORPYRIFOS 20% (n=8) 177.00 46.043 
DIMETHOATE 30% (n=5) 203.80 90.511 
FOLLIDOL (n=9) 130.00 69.937 
PROFENOFOS 20% (n=1) 116.00 . 
profenofos 40% (n=1) 88.00 . 
PROFENOFOS 50% (n=19) 205.32 88.357 
TRIZOPHOS (n=4) 72.50 20.421 
AMYLASE Mean S.D Statistical inference 
CARBOFURAN 3% (n=3) 141.00 64.133 
F=2.522 
.029<0.05 
significant 
CHLORPYRIFOS 20% (n=8) 169.63 85.634 
DIMETHOATE 30% (n=5) 100.20 24.294 
FOLLIDOL (n=9) 120.11 46.812 
PROFENOFOS 20% (n=1) 223.00 . 
profenofos 40% (n=1) 44.00 . 
PROFENOFOS 50% (n=19) 213.84 109.769 
TRIZOPHOS (n=4) 89.00 40.669 
SODIUM Mean S.D Statistical inference 
CARBOFURAN 3% (n=3) 134.67 2.309 F=2.496 
.031<0.05 
significant 
CHLORPYRIFOS 20% (n=8) 134.25 1.581 
DIMETHOATE 30% (n=5) 139.40 3.507 
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FOLLIDOL (n=9) 133.67 1.581 
PROFENOFOS 20% (n=1) 132.00 . 
profenofos 40% (n=1) 132.00 . 
PROFENOFOS 50% (n=19) 135.42 3.254 
TRIZOPHOS (n=4) 132.50 5.916 
POTASSIUM Mean S.D Statistical inference 
CARBOFURAN 3% (n=3) 3.5000 .36056 
F=1.310 
.270>0.05 
Not significant 
CHLORPYRIFOS 20% (n=8) 3.1625 .17678 
DIMETHOATE 30% (n=5) 3.3000 .25495 
FOLLIDOL (n=9) 3.2333 .21794 
PROFENOFOS 20% (n=1) 3.1000 . 
profenofos 40% (n=1) 3.0000 . 
PROFENOFOS 50% (n=19) 3.1579 .22439 
TRIZOPHOS (n=4) 3.3000 .14142 
CALCIUM Mean S.D Statistical inference 
CARBOFURAN 3% (n=3) 8.3667 .37859 
F=2.114 
.063>0.05 
Not significant 
CHLORPYRIFOS 20% (n=8) 8.0125 .36031 
DIMETHOATE 30% (n=5) 8.1200 .43243 
FOLLIDOL (n=9) 6.8111 1.37609 
PROFENOFOS 20% (n=1) 7.2000 . 
profenofos 40% (n=1) 7.9000 . 
PROFENOFOS 50% (n=19) 7.9842 1.01886 
TRIZOPHOS (n=4) 8.3000 .14142 
CPK Mean S.D Statistical inference 
Between Groups   
F=1.340 
.256>0.05 
Not significant 
CARBOFURAN 3% (n=3) 1332.00 2083.677 
CHLORPYRIFOS 20% (n=8) 925.38 780.021 
DIMETHOATE 30% (n=5) 610.20 1141.352 
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FOLLIDOL (n=9) 502.67 683.104 
PROFENOFOS 20% (n=1) 2738.00 . 
profenofos 40% (n=1) 30.00 . 
PROFENOFOS 50% (n=19) 929.74 901.981 
TRIZOPHOS (n=4) 178.00 99.022 
CPK-MB Mean S.D Statistical inference 
CARBOFURAN 3% (n=3) 195.00 306.588 
F=2.219 
0.52>0.05 
Not significant 
CHLORPYRIFOS 20% (n=8) 221.38 220.552 
DIMETHOATE 30% (n=5) 55.00 45.404 
FOLLIDOL (n=9) 147.11 162.806 
PROFENOFOS 20% (n=1) 758.00 . 
profenofos 40% (n=1) 23.00 . 
PROFENOFOS 50% (n=19) 240.21 207.062 
TRIZOPHOS (n=4) 72.00 80.784 
S.AchE Mean S.D Statistical inference 
CARBOFURAN 3% (n=3) 4653.00 4089.317 
F=2.301 
.044<0.05 
significant 
CHLORPYRIFOS 20% (n=8) 1339.88 1337.882 
DIMETHOATE 30% (n=5) 1339.00 720.220 
FOLLIDOL (n=9) 1807.00 1697.805 
PROFENOFOS 20% (n=1) 410.00 . 
profenofos 40% (n=1) 802.00 . 
PROFENOFOS 50% (n=19) 1200.95 827.634 
TRIZOPHOS (n=4) 3484.50 3715.957 
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 By using One-way ANOVA, variations in the individual parameters is 
compared with the compound ingested in poisoning. Though there are huge 
variations in individual parameters caused by the organophosphate compounds 
not all turned out to be statistically significant. Elevation in ALP, Amylase, 
change in Serum Sodium, and fall in serum cholinesterase levels are all 
statistically significant when compared with individual compounds. 
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INTERCORRELATION BETWEEN THE VARIABLES 
Table 32 INTERCORRELATION BETWEEN THE VARIABLES 
 Mean S.D 
 
AST ALT ALP AMYLASE SODIUM POTASSIUM CALCIUM CPK 
CPK-
MB 
S.AchE 
AST 113.48 50.287 
r 1 .683(**) .426(**) .340(*) -.064 -.471(**) -.135 .273 .256 -.359(*) 
Sig. . .000 .002 .016 .661 .001 .348 .055 .073 .010 
ALT 109.62 50.004 
r .683(**) 1 .409(**) .336(*) -.181 -.376(**) -.041 .243 .235 -.319(*) 
Sig. .000 . .003 .017 .208 .007 .777 .089 .100 .024 
ALP 165.96 82.646 
r .426(**) .409(**) 1 .519(**) .293(*) -.227 .340(*) .296(*) .136 -.269 
Sig. .002 .003 . .000 .039 .113 .016 .037 .346 .059 
AMYLASE 160.96 93.453 
r .340(*) .336(*) .519(**) 1 -.083 -.308(*) .192 .442(**) .403(**) -.222 
Sig. .016 .017 .000 . .567 .029 .181 .001 .004 .122 
SODIUM 134.90 3.370 
r -.064 -.181 .293(*) -.083 1 .183 .031 -.097 -.191 .111 
Sig. .661 .208 .039 .567 . .204 .830 .503 .183 .443 
POTASSIUM 3.2140 .22769 
r -
.471(**) 
-
.376(**) 
-.227 -.308(*) .183 1 .119 -.096 -.350(*) .424(**) 
Sig. .001 .007 .113 .029 .204 . .409 .508 .013 .002 
CALCIUM 7.8220 .99453 
r -.135 -.041 .340(*) .192 .031 .119 1 .284(*) .015 -.085 
Sig. .348 .777 .016 .181 .830 .409 . .046 .915 .557 
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CPK 802.38 955.396 
r .273 .243 .296(*) .442(**) -.097 -.096 .284(*) 1 .646(**) -.281(*) 
Sig. .055 .089 .037 .001 .503 .508 .046 . .000 .048 
CPK-MB 191.76 207.497 
r .256 .235 .136 .403(**) -.191 -.350(*) .015 .646(**) 1 -.305(*) 
Sig. .073 .100 .346 .004 .183 .013 .915 .000 . .032 
S.AchE 1712.08 1877.635 
r -.359(*) -.319(*) -.269 -.222 .111 .424(**) -.085 -.281(*) -.305(*) 1 
Sig. .010 .024 .059 .122 .443 .002 .557 .048 .032 . 
   n 50 50 50 50 50 50 50 50 50 50 
** Correlation is significant at the 0.01 level                                     * Correlation is significant at the 0.05 level 
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DISCUSSION 
Organophosphate compounds are widely used as insecticide in 
agriculture. For the reason that they are easily available, accessible and used 
widely, organophosphate toxicity is a significant universal health concern 
mainly in unindustrialized countries. Hundreds of thousands of deaths happen 
worldwide because of organophosphate agents. Organophosphate ingestion is 
one of the supreme cause of suicidal deaths in India. The incidence of pesticide 
poisoning is very common among people of low socio economic status. It may 
be because of rapid urbanisation, economic and social factors that contribute to 
depression and frustration in people. Those persons are the major victims of 
poisoning, when they are not able to cope up with this stressful situations. 
 Inhibition of acetylcholinesterase is the main mechanism by which 
organophosphates act leading to excessive cholinergic stimulation. The clinical 
features of cholinergic storm develops fast, which helps in diagnosing 
clinically that is established by detailed history and biochemical demonstration 
of cholinesterase inhibition. This study is undertaken to analyse the 
biochemical abnormalities in organophosphate poisoning and to assess their 
prognostic significance. 
 In this study the total number of patients were 50. Among them 37 of 
them were male (74%) and 13 of them were female (26%), showing that the 
incidence of poisoning is more in males (Table 1). Among the study group, 
most of the individuals (62%) fall in the age-group of 20 to 30 years (Table 2). 
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This being the most critical period, when the person is likely to face many 
problems leading to psychological stress thus taking drastic steps to end the life 
by consuming toxic substances. There is no statistical significance when Age of 
the patient is compared with the outcome (Table 15) and hence it cannot be 
used as a prognostic indicator. 
 Among the OP agents the most common compound involved in this 
study is Profenofos 50% (n=19) and the next being Follidol (n=9) (Table 3). 
There is no statistical significance when individual compounds are compared 
with the patients’ outcome (Table 17) and hence the OP agent involved in 
poisoning does not predict the outcome.   
Mixing of alcohol with the OP compound before ingestion is seen in 35 
patients (Table 4). Concurrent alcohol and organophosphate consumption is 
common in alcoholic patients, which can lead to consumption of higher 
amounts of OP compounds leading to higher levels of the OP agents in blood 
and higher chance of deaths. This is documented by Eddleston et al(94), but the 
fact taking alcohol along with OP compounds did not affect the outcome in this 
study (Table 18). 
 Most of the patients in this study presented to hospital within 2 - 3 hours 
(66%)        (Table - 5). The average time interval from ingestion of OP agent 
and admission to our emergency ward for a successful outcome is 2.45 hours 
(Table 23), when it exceeds 3.52 hours the outcome is negative. It is 
statistically significant with a P value of <0.05 and hence can be used as a 
prognostic indicator. 
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 In the study patients, the mean quantity of poison ingested is 145.20 ml 
with a SD 61.05. In patients who survived the mean quantity of poison ingested 
is 143.79 ml and those who had a negative outcome ingested 147.14 ml. The 
test of significance gives a P value of 0.850 and hence this parameter does not 
predict the outcome. 
 Out of 50 patients, 29 patients required ventilator support during the 
course of illness in the hospital (Table-8). Out of 29 patients who required 
ventilator support, 18 patients expired. Statistically this is significant with a P 
value of 0.001 <0.05. Hence ventilator requirement can be used to predict 
outcome. 
 The mean values of AST-113.48 IU/L, ALT-109.62 IU/L, ALP- 165.96 
IU/L, and Amylase- 160.96 IU/L is noted among the poisoning patients in this 
study. According to Lohitnavy & Vijayaraghavan(95, 96), there is elevation of 
Serum AST and ALT because of degeneration of hepatocytes and further 
necrosis, causing damage to cell organelles like mitochondria and pouring 
these enzymes into  blood stream(97, 98). The present study also demonstrates 
elevation in liver enzymes following OP poisoning (Table 24). Among the liver 
enzymes ALT elevation shows a statistical significance when compared with 
the outcome and thus can be used as a prognostic indicator. Singh et al(99) found 
elevation of amylase and acute pancreatitis in OP poisoning. Matsumiya N et 
al(100) and Li T Nagayama N et al(101) stated that elevated serum amylase in the 
absence of clinical pancreatitis could be attributed to hypoxemia. Dressel et 
al(102) showed that OP intoxication causes increase in intraductal pressure and 
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increase in exocrine pancreas flow rate resulting in extravasation of fluid. Lin 
CL et al(103) showed that mean amylase level is elevated in patients requiring 
mechanical ventilation and a poorer outcome and a significant negative 
correlation with serum cholinesterase. In our study though there is a negative 
correlation between serum amylase and serum cholinesterase (Table 30) it is 
not found statistically significant. When comparing serum amylase with 
outcome, according to Sumathi et al(104) serum amylase is a good predictor of 
outcome, but in our study there is no statistical significance. 
 The mean serum potassium in our study is 3.2 meq/l (Table 13). 
According to Devanur RMM and Prasad et al(105), poor outcome in OP 
poisoning was noted in patients having respiratory distress with hypokalaemia 
and very low serum cholinesterase. They also found that there was a 
remarkable fall in serum potassium relating to OP toxicity induced weakness of 
muscle and paralysis finally leading to death. The fall in serum potassium was 
proportional to the onset of detrimental signs and symptoms. In our study the 
mean potassium in patients with successful outcome is 3.2 and in patients who 
had a negative endpoint is 3.13. The p value for statistical significance is <0.05 
and hence Serum potassium can be used as a predictor of outcome. 
 The mean CPK in our study is 802.38 IU/L and CPK MB is 191.76 IU/L 
(Table 14. In a study conducted in Egypt by Nermeen AM et al (106) they have 
demonstrated increases in serum CPK and a proportionate fall in serum 
cholinesterase. The excess of acetylcholine in OP poisoning causes reversible 
muscle injury and rise in various muscle enzymes including CPK(107). 
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Dayanand Raddi et al conducted a study regarding CPK and OP poisoning and 
concluded escalation of CPK is evident of respiratory-failure and timely 
estimation of CPK has to be customarily taken as a prognostic indicator in OP 
poisoning(108). ). In acute OP poisoning many cardiac events like arrhythmias, 
non-cardiogenic pulmonary edema, hypertension, conduction defects, and ECG 
changes like transient ST elevation have been documented(109). The mechanism 
behind cardio toxicity of Organophosphates is not known. It is postulated that 
parasympathetic and sympathetic over activity causes myocardial damage. 
Parasympathetic over activity has significant role in coronary artery spasm(109, 
110). In a study conducted by Abbas Aghabiklooei et al (111), they have found out 
elevation of cardiac enzymes in acute OP poisoning and concluded myocardial 
involvement as a most significant cause of negative outcome in OP poisoning. 
They also hypothesised myocardial involvement as a good predictor of 
negative outcome in OP poisoning. In our study also there is a significant 
correlation between CPK, CPK MB (Table 27), and Troponin I (Table 10, 20) 
and the outcome of patient. Hence these three parameters can be used as a 
prognostic indicator in OP poisoning.  
 In our study serum cholinesterase mean value in patients who had 
successful outcome is 2357 IU/L and it is 821 IU/L in those who had a negative 
outcome. According to the cholinesterase values, patients are grouped into four 
groups. Most of the patients in the study group falls into Group 3 with a 
cholinesterase activity of 20% - 50%. Patients in Group 1 and Group 2 with 
very low serum cholinesterase activity had poor prognosis and it is statistically 
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significant (Table 28). According to a study conducted by Yun, HW and Lee, 
DH et al in China, they have concluded absence of increase in cholinesterase 
activity during the course of illness is associated with a poor outcome and 
serial measurements of cholinesterase gives a better guide to the treating 
Physician(112). Nouira et al published that degree of poisoning and serum 
cholinesterase measured on admission has no prognostic value in predicting 
outcome(113). But in our study the serum cholinesterase measured on the day of 
admission predicts the outcome with high statistical significance (Table 26, 
28).  
 There are variations in changes of parameters considering with 
individual OP compounds involved in poisoning. In that Elevation in ALP, 
Change in Serum Sodium and fall in serum cholinesterase all turned out to be 
statistically significant (Table 29) when compared with the individual 
compounds. 
 Using intercorrelations between various parameter in this study the 
significance is noted in following parameters. A fall in serum cholinesterase is 
associated with rise in CPK, fall in serum cholinesterase is associated with a 
fall in serum potassium, and a fall in serum cholinesterase is associated with 
rise in AST and ALT (Table 30). 
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CONCLUSION 
1. Organophosphorus poisoning is more common in adults of age group 20 
– 30 years. 
2. Incidence is high in male patients 
3. Requirement of ventilator support is high, when the patient on 
admission has a higher grade of intoxication clinically ( Using Bardin’s 
grading) 
4. Measurement of Serum potassium and serum cholinesterase is helpful in 
predicting the outcome and prognosis in OP poisoning. Hypokalaemia 
associated with reduced cholinesterase level is related with a negative 
outcome. 
5. Increase in serum creatinekinase is commonly seen in organophosphate 
poisoning. 
6. Increase in CPK MB and Troponin I is commonly seen in 
organophosphate poisoning because of the cardio toxicity involved in 
OP poisoning  
7. CPK, CPK MB and Troponin I have high statistical significance to 
predict prognosis of the patient. 
8. The significant increase of liver enzyme activity and serum amylase 
appears to correlate with clinical severity of the patient in OP poisoning. 
9. Among the liver enzymes and serum amylase, ALT elevation has a 
statistical significance to predict the outcome of the patient. 
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LIMITATIONS 
1. The period of study is minimal, huge data would have been collected if 
done for long time. 
2. Study group is just adequate. 
3. Serial estimation of the biochemical parameters during the course of 
hospital stay is not done. 
4. Troponin I is done in qualitative method and not quantitative method. 
5. Previously undiagnosed cardiac disease is not ruled out in the study 
patients. 
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OPC POISONING CASE PROFORMA 
NAME:   AGE/SEX:  DATE OF ADMISSION: 
PLACE:       COMPOUND: 
MIXED WITH ALCOHOL: 
QUANTITY: 
TIME INTERVAL BETWEEN CONSUMPTION AND FIRST AID: 
CHOLINERGIC SYMPTOMS: 
BARDIN’S GRADE: 
VENTILATORY ASSISSTANCE: 
AST  
ALT  
ALP  
S. AMYLASE  
SODIUM  
POTASSIUM  
CPK  
CPK MB  
TROPONIN I  
S. CHOLINESTERASE  
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Muha;r;rp xg;Gjy; fbjk; 
Muha;r;rp jiyg;G :  
        fp.M.ng.tp];tehjk; muRkUj;Jtf; fy;Yhup 
kw;Wk; kfhj;kh fhe;jp epidT muR kUj;Jtkid> jpUr;rp 
nghJkUj;Jtg; gpuptpy;G+r;rpf; nfhy;yp tp\k; mUe;jp 
Nehahy; ghjpf;fg;gl;l Nehahspfspy; mtu;fSf;F 
,e;Nehapdhy; Vw;gLk; tpisTfis Kd;$l;bNa mwp;aTk;> 
NehapypUe;J Rfk; ngUk; tha;g;G gw;wp mwpa ,uj;jg; 
gupNrhjidapd; %yk; mjw;fhd fhuzpia mse;jwpAk; 
Ma;T. 
ngau;   :                      Njjp  : 
taJ   :                   cs;Nehahsp vz;    : 
,dk;   :                  Muha;r;rp Nru;f;if vz; : 
,e;j Muha;r;rpapd; tptuq;fSk; mjd; Nehf;fKk; 
KOikahfTk; njspthfTk; vdf;F tpsf;fg;gl;lJ. 
vdf;F tpsf;fg;gl;l tp\aq;fis Gupe;Jnfhz;L 
vdJ rk;kjj;ij njuptpf;fpNwd;. 
,e;j Muha;r;rpapy; gpwupd; epu;ge;jkpd;wp vd; 
nrhe;jtpUg;gj;jpd; Ngupy; gq;FngWfpNwd; kw;Wk; ,e;j 
Muha;r;rpapypUe;J ve;NeuKk; gpd;thq;fyhk; vd;gijAk; 
mjdhy; ve;jghjpg;Gk; Vw;glhJ vd;gijAk; ehd; 
Gupe;Jnfhz;Nld;. 
,e;j Muha;r;rpapdhy; Vw;gLk; ed;ikfs; gw;wp 
njspthf kUj;Jtu; %yk; njupe;Jnfhz;Nld;. 
ehd; vd;Dila RaepidTld; kw;Wk; KO 
Rje;jpuj;Jld; ,e;j kUj;Jt Muha;r;rpapy; vd;id 
Nru;j;Jf; nfhs;s rk;kjpf;fpNwd;. 
 
Muha;r;rpahsH ifnahg;gk;      gq;Nfw;ghsH ifnahg;gk; 
ehs;: 
,lk;: 
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ABBREVIATIONS 
 
OP- Organophosphates 
CPK- Creatine phosphokinase 
AST- Aspartate transaminase 
ALT- Alanine transaminase 
ALP- Alkaline phosphatase 
SchE- Serum Cholinesterase 
NTE- Neuropathy target esterase 
FFP- Fresh frozen plasma 
PON1- Paraoxonase 1 
IMS- Intermediate syndrome 
 
 
 
 
 
 
 
 
